SeeThruEquity Initiates Coverage on Verisante Technology, Inc.
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 08/14/13 -- . (TSX VENTURE: VRS) (OTCQX: VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that SeeThruEquity, an investment research firm, has initiated coverage on the Company with a fair value of $1.05 per share.
SeeThruEquity provides research on companies with market capitalizations below $1 billion. The report on Verisante is now available for download - .
About SeeThruEquity, LLC
SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on smallcap and microcap companies with less than $1 billion in market capitalization. These companies have typically been underserved by the traditional Wall Street analyst establishment. We are unfettered by any ties to investment banking or trading, and distribute our high impact research as an approved firm for consensus estimates on Thomson Reuters, CapitalIQ, FactSet, Zacks and StockTwits, as well as to our own audience of investors from our corporate website.
The investment opinions expressed are solely those of SeeThruEquity. SeeThruEquity has not been compensated for the preparation of its report on the Company by any third party or the Company.
About Verisante Technology, Inc.
committed to . The and the utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "" for 2011, awarded a for Innovation in Photonics and an for Excellence in Innovation in 2013. Verisante Core™ was named one of the of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Youtube:
Twitter:
Facebook:
Forward-Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.08.2013 - 07:20 Uhr
Sprache: Deutsch
News-ID 1254661
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 108 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SeeThruEquity Initiates Coverage on Verisante Technology, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Verisante Technology, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
